retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide's mechanisms of action Dual and Triple Gut Peptide

11 (12):e0168396 61

2 Enhanced glycaemic control is crucial for HF patients with T2D, who face increased cardiovascular risks

Partnerships related to GLP-1 drugs have steadily grown in the recent past

European Medicines Agency

diabetes-related healthcare costs exceeded USD 327 billion annually, while research funding for metabolic disorders has increased significantly, supporting innovation and pipeline expansion in GLP-1 drug development

GLP-1 Receptor Agonist Market Report 2026 Global Outlook By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs), By Route Of Administration (Parenteral, Oral), By End Users (Hospitals, Surgical Clinics, Other Users) Market Size, Trends, Strategies, and Forecast to 2035 GLP-1 Receptor Agonist Market Overview GLP-1 Receptor Agonist market size has reached to $14.09 billion in 2025 Expected to grow to $18.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% Growth Driver: Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market Market Trend: Sustained-Release Glp-1 Receptor Agonists Are Gaining Popularity North America was the largest region in 2025 and Asia-Pacific is the fastest growing region